Nature Communications (Dec 2019)
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations
- Satoshi Inoue,
- Yasushi Hirota,
- Toshihide Ueno,
- Yamato Fukui,
- Emiko Yoshida,
- Takuo Hayashi,
- Shinya Kojima,
- Reina Takeyama,
- Taiki Hashimoto,
- Tohru Kiyono,
- Masako Ikemura,
- Ayumi Taguchi,
- Tomoki Tanaka,
- Yosuke Tanaka,
- Seiji Sakata,
- Kengo Takeuchi,
- Ayako Muraoka,
- Satoko Osuka,
- Tsuyoshi Saito,
- Katsutoshi Oda,
- Yutaka Osuga,
- Yasuhisa Terao,
- Masahito Kawazu,
- Hiroyuki Mano
Affiliations
- Satoshi Inoue
- Department of Medical Genomics, The University of Tokyo
- Yasushi Hirota
- Department of Obstetrics and Gynecology, The University of Tokyo
- Toshihide Ueno
- Division of Cellular Signaling, National Cancer Center Research Institute
- Yamato Fukui
- Department of Obstetrics and Gynecology, The University of Tokyo
- Emiko Yoshida
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine
- Takuo Hayashi
- Department of Human Pathology, Juntendo University Faculty of Medicine
- Shinya Kojima
- Division of Cellular Signaling, National Cancer Center Research Institute
- Reina Takeyama
- Division of Cellular Signaling, National Cancer Center Research Institute
- Taiki Hashimoto
- Division of Diagnostic Pathology, National Cancer Center Hospital
- Tohru Kiyono
- Division of Carcinogenesis and Cancer Prevention, and Department of Cell Culture Technology, National Cancer Center Research Institute
- Masako Ikemura
- Department of Pathology, Graduate School of Medicine, The University of Tokyo
- Ayumi Taguchi
- Department of Obstetrics and Gynecology, The University of Tokyo
- Tomoki Tanaka
- Department of Obstetrics and Gynecology, The University of Tokyo
- Yosuke Tanaka
- Division of Cellular Signaling, National Cancer Center Research Institute
- Seiji Sakata
- Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
- Kengo Takeuchi
- Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
- Ayako Muraoka
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine
- Satoko Osuka
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine
- Tsuyoshi Saito
- Department of Human Pathology, Juntendo University Faculty of Medicine
- Katsutoshi Oda
- Department of Obstetrics and Gynecology, The University of Tokyo
- Yutaka Osuga
- Department of Obstetrics and Gynecology, The University of Tokyo
- Yasuhisa Terao
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine
- Masahito Kawazu
- Department of Medical Genomics, The University of Tokyo
- Hiroyuki Mano
- Division of Cellular Signaling, National Cancer Center Research Institute
- DOI
- https://doi.org/10.1038/s41467-019-13708-y
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Uterine adenomyosis often co-occurs with endometriosis or leiomyoma, but little is known about its molecular underpinnings. Here, the authors show that KRAS mutations are frequent in this disease, which might reduce sensitivity to progestin treatment via epigenetic silencing of the progesterone receptor.
